Posted by Michael Wonder on 25 Nov 2021
PHARMAC publishes minutes of August 2021 PTAC meeting
25 November 2021 - Another sparse meeting in terms of the number of new funding applications and funding applications for new medicines.
PHARMAC has published the record of the PTAC meeting held on 19 - 20 August 2021 by videoconference.
The PTAC considered just three funding applications for 'true' new medicines. Not one is a cancer medicine. The outcomes for these medicines are as follows:
- Mirabegron for overactive bladder (clinician application) - recommended
- Risdiplam for spinal muscular atrophy (Roche) - recommended
- Erenumab for migraine (consumer application) - recommended
